{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Mei Mei"],"study_type":["transcription profiling by array"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-15350"],"description":["DRD2 antagonists are commonly used clinically for the treatment of psychiatric disorders. This study aimed to explore the antitumor effects of DRD2 antagonists on a variety of tumor entities. A DRD2 antagonist, pimozide, exhibited antitumor effects in pancreatic, colorectal, ovarian, and gastric cancers. HMOX1 was found to be highly expressed at both mRNA and protein levels, corroborating the results of profiling."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Labeling - The expression profile was carried out at the Microarray Unit of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ)","Sample Collection - From cell lines. All cell lines stored in our lab were authenticated and confirmed to be mycoplasma-negative before starting the experiments. MIA PaCa-2 and PANC-1 were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Thermo Fisher, Germany) with 10% fetal bovine serum (FBS, Gibco). HT-29, HCT 116, and SK-OV-3 were cultured in McCoy’s 5A Medium modified (Gibco) with 10% FBS. MKN45 was cultured in RPMI-1640 (Gibco) with 20% FBS. OVCAR-5 was cultured in RPMI-1640 with 10% FBS. AGS was cultured in F-12K Medium (Gibco) with 10% FBS.","Scaning - The expression profile was carried out at the Microarray Unit of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ)","Nucleic Acid Extraction - The process of obtaining mRNA from cells was performed using the RNeasy Mini Kit (Qiagen, Germany). The concentration was measured using NanoDrop Spectrophotometer ND-1000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA).","Hybridization - The expression profile was carried out at the Microarray Unit of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ)"],"figure_sub":["MIAME Score","Raw Data","Organization","Assays and Data","Processed Data","MAGE-TAB Files","Array Designs"],"pubmed_authors":["Mei Mei","Jörg Hoheisel"],"data_protocol":["Data Transformation - The expression profile was measured by GeneChip Human Genome U133 Plus 2.0 Array, carried out at the Microarray Unit of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ). Chipster ( https://chipster.rahtiapp.fi/home) was used for differential expression analysis. Data were normalized using the Robust Multi-array Average (RMA) normalization method."],"additional_accession":[]},"is_claimable":false,"name":"Transcriptional profile of pimozide-treated cancer cell lines MIA PaCa-2, PANC-1, HT-29, HCT 116, SK-OV-3, OVCAR-5, AGS, MKN45 and DMSO-treated (as control)","description":"DRD2 antagonists are commonly used clinically for the treatment of psychiatric disorders. This study aimed to explore the antitumor effects of DRD2 antagonists on a variety of tumor entities. A DRD2 antagonist, pimozide, exhibited antitumor effects in pancreatic, colorectal, ovarian, and gastric cancers. HMOX1 was found to be highly expressed at both mRNA and protein levels, corroborating the results of profiling.","dates":{"release":"2025-08-01T00:00:00Z","modification":"2025-08-26T10:41:33.702Z","creation":"2025-07-09T15:17:08.342Z"},"accession":"E-MTAB-15350","cross_references":{"EFO":["EFO_0002768","EFO_0002944","EFO_0003814","EFO_0003813","EFO_0005518","EFO_0003816","EFO_0003815"]}}